Shujian Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shujian Lin has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Abigail D. Jeong
Molecular Cellular Developmental Biology, The University of Colorado Boulder, Boulder, Colorado
44 shared publications - Benjamin G. Bitler
Department of OB/GYN, The University of Colorado Anschutz Medical Campus, Aurora, Colorado
44 shared publications - Courtney A. Bailey
Biomedical Engineering Program University of Colorado Boulder Boulder Colorado USA
44 shared publications - Edward B. Chuong
University of Colorado Boulder
44 shared publications - Elizabeth R. Woodruff
Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado
44 shared publications - Fabian R. Villagomez
Division of Reproductive Sciences, Department of Obstetrics and Gynecology, School of Medicine, University of Colorado, Aurora, USA
44 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Hallmark pathways enriched in ID8-OR cells compared to ID8 cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Hallmark pathways enriched in ID8-OR cells compared to ID8 cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Hallmark pathways enriched in ID8-R cells treated with combinatory UNC0642/Olaparib compared to UNC0642 alone.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Hallmark pathways enriched in ID8-R cells treated with combinatory UNC0642/Olaparib compared to UNC0642 alone.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Hallmark pathways negatively enriched in ID8-R cells treated with combinatory UNC0642/Olaparib compared to UNC0642 alone.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Hallmark pathways negatively enriched in ID8-R cells treated with combinatory UNC0642/Olaparib compared to UNC0642 alone.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 10 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Hallmark pathways negatively enriched in ID8-R cells treated with combinatory UNC0642/Olaparib compared to Olaparib alone.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 10 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Hallmark pathways negatively enriched in ID8-R cells treated with combinatory UNC0642/Olaparib compared to Olaparib alone.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 11 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Hallmark pathways enriched in ID8-R cells treated with combinatory EZM8266/Olaparib compared to DMSO control.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 11 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Hallmark pathways enriched in ID8-R cells treated with combinatory EZM8266/Olaparib compared to DMSO control.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Transcriptomics analysis of EZM8266 treatment.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Transcriptomics analysis of EZM8266 treatment.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
EHMT inhibition is well-tolerated and the anti-tumor response is dose-dependent.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
EHMT inhibition is well-tolerated and the anti-tumor response is dose-dependent.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
GSEA of ID8 Olaparib-resistant (ID8-OR) and sensitive (ID8) ovarian cancer cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
GSEA of ID8 Olaparib-resistant (ID8-OR) and sensitive (ID8) ovarian cancer cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Hallmark pathways negatively enriched in ID8-OR cells compared to ID8 cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Hallmark pathways negatively enriched in ID8-OR cells compared to ID8 cells
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Gating strategy and necropsy images following CD8T cell depletion
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Gating strategy and necropsy images following CD8T cell depletion